The various approval timings will be simply a function of FDA's assessment of the initial submission and the subsequent Q&A's that follow in relation to the data contained in the dossier. Whilst a generic has to be the same as the brand (or within very minute deviations), things happen in manufacturing process and deviations occur within the sample statistic data that need to be explained or at worst samples need to be re done.
The luxury of the delays for this dossier is that the market has not formed due to the litigation, so as long as we are approved before an outcome of the litigation its ok. That said the delays would be costing ACR $$ as they address FDA queries.
Delays are really costly when you are racing to enter a market (no legal restrictions) as generic entrant 1,2 or 3 but it turns out you are generic entrant 4,5 or 6.
- Forums
- ASX - By Stock
- ACR
- ACR - Efinaconazole
ACR - Efinaconazole, page-32
-
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
FWD
Queensland's housing crisis an opportunity for ASX builder Fleetwood – and taxpayer cash a safe harbour from the storm
HCH
Hot Chili sets up water company as drought racks Chile–but must also build communities a desal plant
Add ACR (ASX) to my watchlist
|
|||||
Last
6.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $17.44M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 32722 | 6.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.4¢ | 50000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 32722 | 0.061 |
2 | 116666 | 0.060 |
2 | 28810 | 0.058 |
2 | 167543 | 0.057 |
1 | 17857 | 0.056 |
Price($) | Vol. | No. |
---|---|---|
0.064 | 50000 | 1 |
0.065 | 73455 | 1 |
0.070 | 50000 | 1 |
0.072 | 47301 | 1 |
0.073 | 30000 | 3 |
Last trade - 10.46am 11/07/2024 (20 minute delay) ? |
Featured News
CXO
Core Lithium narrowly beats guidance on FY24 spodumene production but 1Y returns still shattered
FWD
Queensland's housing crisis an opportunity for ASX builder Fleetwood – and taxpayer cash a safe harbour from the storm
ACR (ASX) Chart |
Day chart unavailable
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online